Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind comparison of Iomeprol 300 vs 400 for perfusion CT in advanced renal carcinoma
2006-002858-29Phase 4Completed
- Sponsor
- Bracco Imaging
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of iomeprol in renal cell carcinoma (RCC) and metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Bracco Imaging. Primary endpoint: Maximum contrast enhancement in abdominal aorta. Started Sep 2006; status: completed.
02
Drugs
iomeprol
03
Conditions
renal cell carcinoma (RCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2006-002858-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002858-29.